Flt3 - FMS-like tyrosine kinase 3 Gene

中文名称：fms 样酪氨酸激酶3

种属: Mus musculus

同用名: Flk2; Ly72; wmfl; CD135; Flk-2; Flt-3; B230315G04

基因 ID: 14255 | 基因类型: protein coding

关于 Flt3

Chromosome 5: 147,267,551-147,337,299 reverse strand.GRCm39:CM000998.3

This gene has 2 transcripts (splice variants), 134 orthologues, 53 paralogues and is associated with 56 phenotypes. Biased expression in cerebellum adult (RPKM 4.3), spleen adult (RPKM 2.2) and 14 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括磷脂酰肌醇 3-激酶结合活性；蛋白酪氨酸激酶活性；和泛素蛋白连接酶结合活性。参与多个过程，包括常见的骨髓祖细胞增殖；造血作用；和淋巴细胞增殖。作用于几个过程的上游或内部，包括树突细胞稳态；造血或淋巴器官发育；和调节细胞因子的产生。位于质膜外侧。以多种结构表达，包括大脑；背主动脉;免疫系统;生殖系统;和脊髓。用于研究急性髓性白血病和幼年粒单核细胞白血病。该基因的人类直系同源物与急性淋巴细胞白血病有关；急性髓性白血病；结直肠腺癌；肝细胞癌；和前列腺癌。与人类 FLT3（fms 相关受体酪氨酸激酶 3）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including phosphatidylinositol 3-kinase binding activity; protein tyrosine kinase activity; and ubiquitin protein Ligase binding activity. Involved in several processes, including common myeloid progenitor cell proliferation; hemopoiesis; and lymphocyte proliferation. Acts upstream of or within several processes, including dendritic cell homeostasis; hematopoietic or lymphoid organ development; and regulation of cytokine production. Located in external side of plasma membrane. Is expressed in several structures, including brain; dorsal aorta; immune system; reproductive system; and spinal cord. Used to study acute myeloid leukemia and juvenile myelomonocytic leukemia. Human ortholog(s) of this gene implicated in acute lymphoblastic leukemia; acute myeloid leukemia; colorectal adenocarcinoma; hepatocellular carcinoma; and prostate Cancer. Orthologous to human FLT3 (fms related receptor tyrosine kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Flt3 基因产物(1)

mRNA	Protein	Name
NM_010229.2	NP_034359.2	receptor-type tyrosine-protein kinase FLT3 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables cytokine receptor activity	IMP IMP: 通过突变表型推断	18469816	MGI
enables phosphatidylinositol 3-kinase binding	IDA IDA: 通过直接分析推断	8183574	MGI
enables protein binding	IPI IPI: 通过物理相互作用推断	7505204	MGI
enables protein tyrosine kinase activity	IDA IDA: 通过直接分析推断	8384358	MGI
enables ubiquitin protein ligase binding	IPI IPI: 通过物理相互作用推断	23418353	MGI

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in B cell differentiation	IMP IMP: 通过突变表型推断	21228325	MGI
acts upstream of or within antigen processing and presentation	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of cell population proliferation	IMP IMP: 通过突变表型推断	7919361	MGI
involved in cellular response to cytokine stimulus	IMP IMP: 通过突变表型推断	18469816	MGI
acts upstream of or within cellular response to virus	IMP IMP: 通过突变表型推断	20457904	MGI
involved in common myeloid progenitor cell proliferation	IMP IMP: 通过突变表型推断	21813452	MGI
involved in cytokine-mediated signaling pathway	IMP IMP: 通过突变表型推断	18469816	MGI
involved in dendritic cell differentiation	IMP IMP: 通过突变表型推断	18469816	MGI
acts upstream of or within dendritic cell homeostasis	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within homeostasis of number of cells within a tissue	IGI IGI: 通过遗传相互作用推断	22674806	MGI
acts upstream of or within homeostasis of number of cells within a tissue	IMP IMP: 通过突变表型推断	20457904	MGI
involved in leukocyte homeostasis	IMP IMP: 通过突变表型推断	18469816	MGI
acts upstream of or within lymph node development	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within lymphocyte differentiation	IDA IDA: 通过直接分析推断	12387740	MGI
involved in lymphocyte proliferation	IMP IMP: 通过突变表型推断	18469816	MGI
acts upstream of or within lymphoid progenitor cell differentiation	IGI IGI: 通过遗传相互作用推断	7621074	MGI
acts upstream of or within myeloid progenitor cell differentiation	IGI IGI: 通过遗传相互作用推断	7621074	MGI
acts upstream of or within myeloid progenitor cell differentiation	IMP IMP: 通过突变表型推断	18245664	MGI
involved in myeloid progenitor cell differentiation	IMP IMP: 通过突变表型推断	18469816	MGI
acts upstream of or within negative regulation of B cell differentiation	IDA IDA: 通过直接分析推断	16618805	MGI
acts upstream of or within negative regulation of cell population proliferation	IMP IMP: 通过突变表型推断	7919361	MGI
acts upstream of or within negative regulation of interleukin-6 production	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within negative regulation of tumor necrosis factor production	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within positive regulation of interferon-alpha production	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within positive regulation of interleukin-12 production	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within positive regulation of multicellular organism growth	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within positive regulation of protein phosphorylation	IGI IGI: 通过遗传相互作用推断	20360400	MGI
acts upstream of or within positive regulation of type II interferon production	IMP IMP: 通过突变表型推断	20457904	MGI
acts upstream of or within post-embryonic development	IGI IGI: 通过遗传相互作用推断	22674806	MGI
acts upstream of or within pro-B cell differentiation	IMP IMP: 通过突变表型推断	7621074	MGI
involved in pro-B cell differentiation	IMP IMP: 通过突变表型推断	21228325	MGI
acts upstream of or within pro-T cell differentiation	IMP IMP: 通过突变表型推断	7621074	MGI
acts upstream of or within protein autophosphorylation	IDA IDA: 通过直接分析推断	8183574	MGI
acts upstream of protein phosphorylation	IGI IGI: 通过遗传相互作用推断	20360400	MGI
acts upstream of or within spleen development	IGI IGI: 通过遗传相互作用推断	22674806	MGI

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cell surface	IDA IDA: 通过直接分析推断	7630197	MGI
located in external side of plasma membrane	IDA IDA: 通过直接分析推断	23528453	MGI

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Flt3 蛋白结构

7tm_GPCRs

PKc_like

0
200
400
600
800
1000 a.a.

蛋白主名

其他名称

receptor-type tyrosine-protein kinase FLT3

FL cytokine receptor	fetal liver kinase 2
tyrosine-protein kinase FLT3	tyrosine-protein kinase receptor flk-2

重组 Flt3 蛋白

目录号	产品名	蛋白编号	纯度
HY-P74151	FLT3 Protein, Mouse (HEK293, His)	Q3UEW6/NP_034359.2 (N28-S544)	≥95%

相关产品

Approval

生物活性分子 (17)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10201	Sorafenib	Inhibitor	99.92%	是
HY-13016	Cabozantinib	Inhibitor	99.96%	是
HY-12432	Gilteritinib	Inhibitor	99.69%	是
HY-13001	Quizartinib	Inhibitor	99.01%	是
HY-16379	Pacritinib	Inhibitor	99.93%	是
HY-10201A	Sorafenib Tosylate	Inhibitor	99.91%	是
HY-13038A	Fostamatinib	Inhibitor	99.50%	是
HY-112306	Ripretinib	Inhibitor	98.90%	是
HY-10201S	Sorafenib-d3	Inhibitor	99.57%	否
HY-50867	Lestaurtinib	Inhibitor	99.17%	否
HY-12432A	Gilteritinib hemifumarate	Inhibitor	99.75%	是
HY-13038	Fostamatinib Disodium	Inhibitor	99.88%	是
HY-13038B	Fostamatinib disodium hexahydrate	Inhibitor	99.73%	是
HY-12432R	Gilteritinib (Standard)	Inhibitor	/	否
HY-10201R	Sorafenib (Standard)	Inhibitor	/	否
HY-14217	Quizartinib dihydrochloride	Inhibitor	99.81%	否
HY-13016A	Cabozantinib hydrochloride	Inhibitor	/	否

Clinical Phase

生物活性分子 (33)

目录号	产品名	作用方式	纯度	Phase
HY-50751	Linifanib	Inhibitor	99.28%	Phase 3
HY-50514	AT9283	Inhibitor	99.67%	Phase 3
HY-16961	Sitravatinib	Inhibitor	99.57%	Phase 3
HY-50905	Dovitinib	Inhibitor	99.88%	Phase 3
HY-10207	Dovitinib lactate	Inhibitor	99.75%	Phase 3
HY-16961A	Sitravatinib malate	Inhibitor	/	Phase 3
HY-B0062	Dovitinib lactate hydrate	Inhibitor	/	Phase 3
HY-16379B	Pacritinib citrate	Inhibitor	/	Phase 3
HY-13024	Rebastinib	Inhibitor	99.91%	Phase 2
HY-135317	Emavusertib	Inhibitor	99.94%	Phase 2
HY-15514	Merestinib	Inhibitor	99.99%	Phase 2
HY-13034	Gandotinib	Inhibitor	99.82%	Phase 2
HY-10206	Amuvatinib	Inhibitor	99.47%	Phase 2
HY-10987A	ENMD-2076	Inhibitor	99.12%	Phase 2
HY-10202	Tandutinib	Inhibitor	99.48%	Phase 2
HY-100867A	Mivavotinib monohydrochloride	Inhibitor	99.91%	Phase 2
HY-145015	Tuspetinib		99.85%	Phase 2
HY-10987	ENMD-2076 Tartrate	Inhibitor	99.42%	Phase 2
HY-10202A	Tandutinib hydrochloride	Inhibitor	99.78%	Phase 2
HY-118304B	AKN-028 acetate	Inhibitor	99.95%	Phase 2
HY-15514A	Merestinib dihydrochloride	Inhibitor	99.36%	Phase 2
HY-100867	Mivavotinib	Inhibitor	/	Phase 2
HY-118304	AKN-028	Inhibitor	/	Phase 2
HY-10206A	Amuvatinib hydrochloride	Inhibitor	/	Phase 2
HY-10339	KW-2449	Inhibitor	99.69%	Phase 1
HY-10032	PF 477736	Inhibitor	99.21%	Phase 1
HY-B0791	Altiratinib	Inhibitor	98.05%	Phase 1
HY-101549	MRX-2843	Inhibitor	99.70%	Phase 1
HY-111361	FN-1501	Inhibitor	99.08%	Phase 1
HY-139535	Luxeptinib	Inhibitor	99.30%	Phase 1
HY-13072	Cenisertib	Inhibitor	99.86%	Phase 1
HY-13223A	Crenolanib benzenesulfonate	Inhibitor	/	Phase 1
HY-118084	LS-104	Inhibitor	/	Phase 1

Pre-clinical Phase

生物活性分子 (149)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12067	R406	Inhibitor	98.72%	否
HY-13223	Crenolanib	Inhibitor	99.68%	是
HY-12344	UNC2025	Inhibitor	99.83%	否
HY-15166	(E/Z)-Zotiraciclib	Inhibitor	99.96%	否
HY-13263	CHIR-124	Inhibitor	98.57%	否
HY-12461	WS6	Modulator	99.94%	否
HY-153886	Wu-5	Inhibitor	99.34%	否
HY-11108	R406 free base	Inhibitor	99.80%	否
HY-15002	AST 487	Inhibitor	99.42%	否
HY-10410	TG101209	Inhibitor	99.22%	否
HY-12344A	UNC2025 hydrochloride	Inhibitor	99.87%	否
HY-13894	Tyrphostin AG1296	Inhibitor	99.69%	否
HY-132200	UNC5293	Inhibitor	95.07%	否
HY-N0071	Crotonoside	Inhibitor	99.64%	否
HY-12333	Denfivontinib	Inhibitor	≥98.0%	否
HY-145723	MAX-40279	Inhibitor	97.10%	否
HY-120758	SEL24-B489	Inhibitor	99.02%	否
HY-15889	AMG 925	Inhibitor	98.20%	否
HY-153857	PHI-101	Inhibitor	98.97%	否
HY-12420	JNJ-47117096 hydrochloride	Inhibitor	99.68%	否
HY-15166B	(E/Z)-Zotiraciclib citrate	Inhibitor	98.06%	否
HY-130247	Flonoltinib	Inhibitor	99.79%	否
HY-15003	ATH686	Inhibitor	99.38%	否
HY-18161	CCT241736	Inhibitor	99.88%	否
HY-18952A	(Z)-SU5614	Inhibitor	98.43%	否
HY-13907	TCS 359	Inhibitor	99.89%	否
HY-114323	PROTAC FLT-3 degrader 1	Inhibitor	99.74%	否
HY-131906	JAK2-IN-7	Inhibitor	99.15%	否
HY-130247A	Flonoltinib TFA	Inhibitor	99.77%	否
HY-13016S	Cabozantinib-d6	Inhibitor	98.14%	否
HY-112145	FLT3-IN-3	Inhibitor	99.95%	否
HY-120590	Ruserontinib	Inhibitor	99.82%	否
HY-15166A	(E/Z)-Zotiraciclib hydrochloride	Inhibitor	99.90%	否
HY-13493	AC710	Inhibitor	98.56%	否
HY-162037	CDDD11-8	Inhibitor	99.62%	否
HY-18744	FLT3-IN-2	Inhibitor	95.80%	否
HY-148070	FLT3-IN-17	Inhibitor	99.56%	否
HY-107417	Hypothemycin	Inhibitor	≥98.0%	否
HY-18179	AZD2932	Inhibitor	99.04%	否
HY-132150A	HPK1-IN-2 dihydrochloride	Inhibitor	98.69%	否
HY-19897	4SC-203	Inhibitor	98.98%	否
HY-148036	FLT3-IN-16	Inhibitor	98.98%	否
HY-151904	AXL-IN-13		98.03%	否
HY-12432S1	Gilteritinib-d8	Inhibitor	≥98.0%	否
HY-124502	UNC4203	Inhibitor	99.80%	否
HY-12960	SKLB4771	Inhibitor	98.08%	否
HY-144869	OTS447	Inhibitor	99.83%	否
HY-128572	FLT3-IN-6	Inhibitor	99.14%	否
HY-145723C	MAX-40279 hemiadipate	Inhibitor	99.26%	否
HY-15496	E6201	Inhibitor	/	否
HY-128571	FLT3-IN-4	Inhibitor	98.19%	否
HY-100865	BPR1K871	Inhibitor	99.12%	否
HY-110026	GTP-14564	Inhibitor	99.91%	否
HY-153473	FLT3-IN-19	Inhibitor	99.19%	否
HY-13537A	BPR1J-097 Hydrochloride	Inhibitor	99.20%	否
HY-143286A	PF15 TFA	Degrader	99.72%	否
HY-134481	FLT3-IN-10	Inhibitor	98.80%	否
HY-110293	CHMFL-FLT3-122	Inhibitor	98.47%	否
HY-15889A	AMG 925 HCl	Inhibitor	/	否
HY-15198	KG5	Inhibitor	99.79%	否
HY-13537	BPR1J-097	Inhibitor	/	否
HY-108263	3-Hydroxy Midostaurin	Inhibitor	97.02%	否
HY-135317B	Emavusertib hydrochloride	Inhibitor	/	否
HY-145015A	Tuspetinib hydrate	Inhibitor	/	否
HY-145723A	MAX-40279 hydrochloride	Inhibitor	/	否
HY-146749	FLT3/TrKA-IN-1	Inhibitor	/	否
HY-145723B	MAX-40279 hemifumarate	Inhibitor	99.56%	否
HY-112475	Flt-3 Inhibitor III	Inhibitor	/	否
HY-155341	HSK205	Inhibitor	/	否
HY-108263S	3-Hydroxy Midostaurin-d5	Inhibitor	/	否
HY-158265	FLT3D835Y/F691L-IN-1	Inhibitor	/	否
HY-161708	PROTAC FLT3/CDKs degrader-1	Degrader	/	否
HY-139619	LT-850-166	Inhibitor	/	否
HY-155112	Antiproliferative agent-30	Inhibitor	/	否
HY-143894	FLT3-IN-11	Inhibitor	/	否
HY-145904	PDGFRα/FLT3-ITD-IN-3	Inhibitor	/	否
HY-144711	FLT3/ITD-IN-3	Inhibitor	/	否
HY-149539	PLM-101	Inhibitor	/	否
HY-145690	HP1328	Inhibitor	/	否
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	否
HY-10201S2	Sorafenib-13C,d3	Inhibitor	98.35%	否
HY-158325	PROTAC FLT-3 degrader 4	Inhibitor	/	否
HY-162906	FLT3/HDAC-IN-2	Inhibitor	/	否
HY-145903	PDGFRα/FLT3-ITD-IN-2	Inhibitor	/	否
HY-111249	TTT 3002	Inhibitor	/	否
HY-162032	FLT3-IN-25	Inhibitor	/	否
HY-162936	SILA-123	Inhibitor	/	否
HY-146886	FLT3-IN-15	Inhibitor	/	否
HY-143434	FLT3/D835Y-IN-1	Inhibitor	/	否
HY-108263B	(R)-3-Hydroxy Midostaurin	Inhibitor	/	否
HY-18949	JI6	Inhibitor	/	否
HY-144777	FLT3-IN-14	Inhibitor	/	否
HY-148521	PROTAC FLT3/CDK9 degrader-1	Degrader	/	否
HY-155594	LT-540-717	Inhibitor	/	否
HY-155770	FLT3-IN-20	Inhibitor	/	否
HY-144710	FLT3/ITD-IN-2	Inhibitor	/	否
HY-151945	TRK II-IN-1	Inhibitor	/	否
HY-143895	FLT3-IN-12	Inhibitor	/	否
HY-150582	c-Met-IN-14	Inhibitor	/	否
HY-169076	FLT3/HDAC-IN-1	Inhibitor	/	否
HY-145691	HP1142	Inhibitor	/	否
HY-160848	FLT3/ITD-IN-5	Inhibitor	/	否
HY-157213	LWY713	Degrader	/	否
HY-108263A	(S)-3-Hydroxy Midostaurin	Inhibitor	/	否
HY-149474	HDAC-IN-63	Inhibitor	/	否
HY-161323	FLT3-ITD/D835Y-IN-1	Inhibitor	/	否
HY-15163A	Zotiraciclib hydrochloride	Inhibitor	/	否
HY-156410	FLT3-IN-23	Inhibitor	/	否
HY-50905S	Dovitinib-d8	Inhibitor	/	否
HY-161280	PROTAC FLT-3 degrader 3	Degrader	/	否
HY-144709	FLT3/ITD-IN-1	Inhibitor	/	否
HY-143278	FLT3-IN-13	Inhibitor	/	否
HY-103464	5'-Fluoroindirubinoxime	Inhibitor	≥98.0%	否
HY-115906	K783-0308	Inhibitor	/	否
HY-151961	RSH-7	Inhibitor	99.07%	否
HY-145902	PDGFRα/FLT3-ITD-IN-1	Inhibitor	/	否
HY-161967	JAK2/FLT3-IN-3	Inhibitor	/	否
HY-155226	FLT3-IN-21	Inhibitor	/	否
HY-162367	FLT3/CHK1-IN-2	Inhibitor	/	否
HY-146680	FLT3/ITD-IN-4	Inhibitor	/	否
HY-143286	PF15	Inhibitor	/	否
HY-163068	FLT3-IN-24	Inhibitor	/	否
HY-13016S1	Cabozantinib-d4	Inhibitor	/	否
HY-123237	KRC-108	Inhibitor	/	否
HY-148522	FLT3-IN-18	Inhibitor	/	否
HY-115904	FLT3/CDK4-IN-1	Inhibitor	/	否
HY-161709	FLT3/CDKs ligand-1	Degrader	/	否
HY-155302	FLT3-IN-22	Inhibitor	/	否
HY-15519	LBW242	Inhibitor	/	否
HY-139996	Pomalidomide-C5-Dovitinib	Inhibitor	/	否
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	否
HY-112378	D-65476	Inhibitor	/	否
HY-125051	SG3-179	Inhibitor	/	否
HY-10201S1	Sorafenib-d4	Inhibitor	/	否
HY-122240	AAE871	Inhibitor	/	否
HY-168213	FLT3-IN-27	Inhibitor	/	否
HY-148036S	FLT3-IN-16-d1	Inhibitor	/	否
HY-116129	BPR1J-340	Inhibitor	/	否
HY-112417	Ki11502	Inhibitor	/	否
HY-118304A	AKN-028 TFA	Inhibitor	/	否
HY-15163	Zotiraciclib	Inhibitor	/	否
HY-13072B	Cenisertib benzoate	Inhibitor	/	否
HY-130247B	Flonoltinib monomaleate	Inhibitor	/	否
HY-101549A	MRX-2843 hydrochloride	Inhibitor	/	否
HY-112350	AGL 2043	Inhibitor	/	否
HY-123201	KRN383 analog	Inhibitor	/	否
HY-50751S	Linifanib-d4	Inhibitor	/	否
HY-10058	AT9283 lactic acid	Inhibitor	/	否
HY-111545	BSc5371	Inhibitor	/	否

抗体抑制剂 (2)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P99916	Emirodatamab		/	否
HY-P990786	Anti-FLT3 Antibody (AGS62P)	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Flt3	NCBI	NCBI:2322
Macaca fascicularis	Flt3	NCBI	NCBI:102144988
Susscrofa domestica	Flt3	NCBI
Rattus norvegicus	Flt3	NCBI	NCBI:140635
Macaca mulatta	Flt3	NCBI	NCBI:721712

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.